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Abstract
In this work we use complex network theory to provide a statistical model of the connectivity patterns of human proteins
and their interaction partners. Our intention is to identify important proteins that may be predisposed to be potential
candidates as drug targets for therapeutic interventions. Target proteins usually have more interaction partners than
non-target proteins, but there are no hard-and-fast rules for defining the actual number of interactions. We devise
a statistical measure for identifying hub proteins, we score our target proteins with gene ontology annotations. The
important drugable protein targets are likely to have similar biological functions that can be assessed for their potential
therapeutic value. Our system provides a statistical analysis of the local and distant neighborhood protein interactions
of the potential targets using complex network measures. This approach builds a more accurate model of drug-to-target
activity and therefore the likely impact on treating diseases. We integrate high quality protein interaction data from
the HINT database and disease associated proteins from the DrugTarget database. Other sources include biological
knowledge from Gene Ontology and drug information from DrugBank. The problem is a very challenging one since
the data is highly imbalanced between target proteins and the more numerous nontargets. We use undersampling on
the training data and build Random Forest classifier models which are used to identify previously unclassified target
proteins. We validate and corroborate these findings from the available literature.
Keywords: Complex network theory, link-clustering, protein interactions, ontologies
1. Introduction
Protein interactions play a key role in the majority of
activities occurring in the cell and participate in commu-
nications between cells [24]. The connectivity patterns of
the interacting proteins can be modeled by complex net-
work theory (graph theory) which can provide a statistical
explanation of these activities and processes [21]. Integrat-
ing clustering methods with complex networks has enabled
further insights, revealing the modular nature of proteins
[28]. Proteins are often cooperate in modules and may be
shared between several different cellular activities. Those
proteins with a large number of verified interactions are
classed as hub proteins. If they are implicated in one
disease it is possible they may be participating in other
disorders [23]. It should be noted that high connectivity
(degree) or hubness does not necessarily imply that a given
protein is important in some way with respect to disease.
In this work we investigate the degree of protein connec-
tivity patterns and also the location of a proteins position
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in the local network with respect to its predisposition to
be a drug target.
The majority of disease causing genes are generally im-
plicated with a single or small number of disorders al-
though there are striking exceptions. The tumor sup-
pressor gene TP53 appears to be involved with up to ten
related diseases [12]. This gives credence to the disease
network theory which is providing a new insights regard-
ing how diseases occur [5]. Some diseases are more dif-
ficult to resolve, often a module of cooperating proteins
can compensate for malfunctions of individual proteins.
Consequently, making the identification of the faulty bio-
logical process more difficult to identify [17]. The idea of
structural motifs may be a good candidate to help resolve
the challenges such as cellular organization [3]. We can
improve our knowledge and understanding of the mecha-
nisms of disease based on a better understanding of pro-
tein targets and non-targets and may suggest alternative
therapeutic interventions [13, 22].
However, any potential for a protein to be drug tar-
get implies it must possess a particular shape that can
bind/interact with drug-like molecules i.e. it must con-
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Figure 1: Small fraction of the protein network with drug targets colored yellow and slightly larger in size, non-targets are colored light blue.
However, based on their connectivity patterns their biological and complex network statistics some of the non-targets may be prove to be
viable drug targets.
tain a binding site. Recent research has investigated the
role of the types of proteins such as G-protein coupled
receptors, ion channels and kinases [7]. This work deter-
mined that a proteins relationship to the membrane and
it’s hydrophobicity may play an important role. However,
it does beg the question, how many potential protein tar-
gets are out there? [25]. One analysis suggested there
may be between 2000-3000 proteins that are potentially
druggable candidates [26]. Another approach was able to
identify 668 proteins that are currently not drug targets
but that have target-like potential [2]. Some proteins may
be completely undruggable, while others can only be per-
turbed by targeting their network neighborhood proteins.
Currently, complete knowledge of the proteome and inter-
action targets is some years away from completion [4].
1.1. Related work
The technique developed by Yu et al, considers the prob-
lem as one of module distance estimation with the under-
standing that the human interactome is still incomplete
and with all the uncertainty inherent [31]. Yu’s ultimate
goal was concerned with repositioning drugs for different
diseases. The modules are composed of drug-protein pairs
and all are involved with cancer specific functions. The
disease module distance metric was able to identify several
candidate drugs. The MBiRW method developed by Luo
et al uses a bi-random walk to measure similarity of drugs
and diseases [20]. MBiRW uses novel similarity measures
and is well validated against gold standard data but lacks
target information and biologically relevant information.
The CommWalker algorithm devised by Luecken uses a
random walk approach to sample the proteins assigned to
functional modules [19]. For robustness, the modules are
formed by three different link analysis procedures and an
average walk will produce a goodness of fit value. The
walks are terminated when they have approach a critical
value. At each step the functional GO annotation is aver-
aged out to calculate the module homogeneity, scores are
then combined to enable each module to be ranked on its
biological plausibility.
The closest work to ours tackles the challenges and op-
portunities of integrating biological knowledge in the form
of annotations from gene ontology (GO). For example, Hs-
ing et al used GO to build classifiers to identify hub pro-
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teins which are highly connected proteins with many in-
teraction partners [14]. However, the classifiers performed
badly on some proteins through lack of suitable annota-
tions. Work by Zhang et al explored the issues of identify-
ing protein interaction partners through use of GO terms
[32]. Support Vector Machine classifiers were constructed
on the GO annotated PPI data and good accuracy was
achieved on predicting the likely interaction partners. Re-
search by Fu et al explored the likelihood that intrinsic
disorder proteins will form highly interconnected hubs and
potentially drug targets [11]. Again, the usefulness of GO
was employed to annotate and analyze the relationships.
We extend all this previous work by adding novel anal-
ysis of the hub and target proteins using complex network
theory and community structure of the protein interac-
tions. Furthermore, we annotate the protein interactions
with GO terms to help identify novel protein targets. Thus
we are able to generate target protein candidates for use by
other researchers to conduct biological experiments in the
lab. The remainder of this is paper is structured as follows:
section two discusses the methods including the architec-
ture of our system and the sources of data and knowledge,
section three describes the experimental results, section
four presents the discussion and finally section five presents
the conclusions and future work.
2. Materials and methods
2.1. Data and knowledge sources
The candidate drugs have known on-target and off-
target proteins, this knowledge is augmented by ac-
cessing protein-to-protein interactions found in the
HINT database [8]. This database contains high-
quality protein-protein interactions from 8 interactome re-
sources (BioGRID, MINT, iRefWeb, DIP, IntAct, HPRD,
MIPS and the PDB). The database contains 12,429
unique proteins with 59,128 interactions between them.
http://hint.yulab.org/. This data was further aug-
mented by high quality protein interactions from the Bio-
Plex database maintained by Harvard Medical School
(http://bioplex.hms.harvard.edu/) [15].
Drug and protein target data was obtained from Drug-
Central, this is a comprehensive drug information resource
for FDA drugs and drugs approved outside USA. The re-
sources can be searched using: drug, target, disease, and
pharmacological action. The information resource is cre-
ated and maintained by the Division of Translational Infor-
matics at University of New Mexico. (as of 8th January
2018, http://drugcentral.org/). The data is particularly
suited for our purposes, because we use the drugname,
protein targets and protein type [27].
The data is highly imbalanced between the target pro-
teins (1,449) and the nontargets (10,567). The data are
randomly divided into three groups, table 1 indicates the
split and objective of each data set. The training data
consist of 724 targets and 5,284 nontargets, the test data
is similarly unbalanced. The Exploratory data consists of
1,000 nontargets reserved for identifying potential targets.
Table 1: Composition of data
Data id No targets No nontargets Purpose
T 724 5,284 Training
TE 725 5,283 Testing
NT 0 1,000 Exploratory data
We select the best method of down sampling on the
training data based on the accuracy and other statistics
gained from the random forest classifiers.
Gene ontology (GO) provides useful biological informa-
tion and it is recognized as the de facto standard for gene
product annotation [1]. This enables an assessment to
be made regarding the biological plausibility of the inter-
acting proteins and to observe the extent they actually
cooperate in viable biological functions rather than ran-
dom or spurious associations. The GO terms are organized
to represent the three main aspects of biology: molecular
functions (MF), cellular components (CC) and biological
process (BP). For each protein, enrichment was performed
using the GO-slim version of the gene ontology (GO). The
enrichment method is based on similarity measures using
information content techniques [9]. We mapped our low-
level annotations to several high-level GO-slim terms, in
our generic version 149 terms are available.
All proteins without GO terms are removed and
the remaining proteins are annotated the GO-slim
version (http://www.geneontology.org/page/go-slim-and-
subset-guide) simplifies the terms. GO-slims are subsets
of terms in the ontology that give a broad overview of the
ontology content. GO-slims do this without including the
detail of the specific fine grained terms and therefore sim-
plify computational model building. We discovered that
accuracy is not greatly compromised since we obtain ac-
curacy’s that are comparable to other work that uses the
full GO terms [9].
The GO-slim annotated proteins are used to build a
Random Forest classifier [6]. Random Forests are a su-
pervised ensemble classification technique requiring class
labels, where a group of weak models combine to form a
powerful model. Several decision trees are created (hence
a forest) with random sampling used as the attribute to
split on, there is a direct correlation between the number
of trees in the forest and the accuracy. Another important
advantage of the Random Forest classifier is that the pre-
dictor variables are ranked according to importance using
the Gini impurity measure and is used for the calculation
of splits during training.
The Random Forest was assessed using standard
classifier metrics:
Accuracy = (TP + TN) / (TP+ TN + FP + FN)
Sensitivity = TP / (TP + FN)
Specificity = TN / (TN + FP)
PPV = TP / (TP + FP)
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NPN = TN / (TN + FN)
Where: TP is a True Positive, TN is a True Negative,
FP is a False Positive and FN is a False Negative. PPV is
the Positive Predictive Value and the NPV is the Negative
Predictive Value. ROC and PR curves were plotted using
these values.
2.2. Software implementation and availability
The analysis was conducted using the R language (ver-
sion 3.4.4) with the RStudio programming environment.
We used an Intel Xenon CPU, 64-bit (3.2GHz) with 128
GB of RAM. The R software written by other researchers
included the igraph package by Kolaczyk [16] along with
other packages for data manipulation, transformations and
plotting include: ggplot2, dplyr and ontologySimilarity.
The RandomForest package by Liaw allowed the building
and testing of the classifier models [18]. The R code that
created the data, diagrams, tables and charts described in
this paper are freely available on GitHub for download:
https://github.com/kenmcgarry/ComplexNetworks
2.3. Complex network theory
Graph theoretic methods are suitable to any application
where the entities of interest are linked together through
various associations or relationships. Quite diverse appli-
cation areas such as social network analysis and biologi-
cal networks are particularly suited to the mathematics of
graph construction, traversal and inferencing. A graph G
= (V, E) consists of a set of nodes often called vertices V
and a set of links called edges E. The links in this case are
undirected, that is to say there is no implied direction to
the relationship in the sense that A causes B.
The criteria we use to determine the relevance of disease
connectivity is based upon recent discoveries. It is likely
that the essential genes and the disease genes encode the
hubs [28] and that gene network topology is unlikely to
encode the information to deduce disease modules [12].
In algorithm 1, we detail our computational methods of
discovering the disease modules.
Closeness centrality (CC) of protein i is the sum of
graph-theoretic distances from all other proteins in the
network, where the distance d(vi, vj) from one protein i to
another j is defined as the number of links in the short-
est path from one to the other, where N is the number
of all proteins in the network. The closeness centrality of





Betweenness centrality assesses the extent of influence
a protein has in facilitating communication between pairs
of proteins and is defined as the fraction of shortest paths
going through a given node [10]. In the PPI network, then







Where: σ(s, t, |v) is the total number of distinct shortest
paths from node s to node t passing through v, σ(s, t) is
the total number of shortest paths between node s and
node t irrespective of whether they pass through node v
or not.
Complex networks (graph theory) can generate very
large structures in real-world applications, often consist-
ing of thousands of nodes and tens of thousands of con-
nections. This results in a common task to query if two
particular nodes are connected and if so how distant are
they are. Detection and assessment of the shortest path
is important to centrality measures and can be defined as
when two nodes i and j are connected if there exists a
sequence of connections that connect i and j. The length
of a path is the number of connections between them, de-
noted by dij . In biology, two proteins may not interact
directly but may communicate through a signaling cas-
cade of other proteins. Small path lengths from tightly
coupled networks tend to give high clustering coefficients
as derived by equation 3, random networks have low clus-
tering coefficients compared with real-world networks.
Ci =
2 | {ejk} |
ki(ki − 1)
: vj , vk ∈ Ni, eij ∈ E (3)
Where V = v1, v2...vn are a set of n vertices and E a set
of edges, where eij denotes an edge between vertices vi and
vj ki refers to the vertex neighbours. The neighbourhood
N , for a vertex vi, is its immediately connected neighbors
as follows:
Ni = {vj} : eij ∈ E (4)
The degree ki of a vertex is the number of vertices in
its neighborhood |Ni|. Making the clustering coefficient
Ci for a vertex vi the proportion of links between the ver-
tices within its neighborhood divided by the number of
links that could possibly exist between them. In addi-
tion undirected graphs have the property that eij and eji
are considered identical. Therefore, if a vertex vi has ki
neighbor, only the following edges could exist among the
vertices within the neighborhood.
The clustering coefficient is used to estimate the den-
sity of the immediate neighborhood of each vertex and
formally, for undirected graph G = (V : E), define the
neighbor set of vi ∈ V , denoted by Nvi . A high cluster
coefficient indicates a high level of interconnection between
members of a node’s neighboring nodes. These measures
return a value of one if every neighbor connected to vi
is also connected to every other vertex within the neigh-
borhood n, and zero if no vertex that is connected to vi
connects to any other vertex that is connected to vi. The
clustering coefficient for the entire network is the average








We therefore expect that hub proteins on average have
a higher clustering coefficients than non-hubs. This was
confirmed by our experimental work but the important
proteins are not identified by connectivity numbers alone,
the location of a key protein is also by its position (topol-
ogy) in the network.
Algorithm 1
Build Random Forest classifier and complex network
1: procedure Build RF Classifier(HINT,DrugTarget,GO − slim)
2: do initialize
3: protein list ← annotate with target/nontarget labels
4: protein list ← annotate with GO-Slim
5: Remove proteins with < 1 GO-Slim annotation
6: NT (unseen data) ← randomly select 1,000 nontargets
7: T (train data) ← 50/50 split target/nontarget
8: TE (test data)← 50/50 split target/nontarget
9: proteins matrix ← convert list to binary matrix
10: end initialize
11:
12: PPInetwork ← igraph builds complex network
13: NetStatistics ← calculate k-coreness for all nodes
14:
15: while
16: accuracy≤accuracy from last iteration do
17: RF parameters← (Num Trees, Cutoff )
18: RF accuracy← test data (TE)
19: modify RF sampling ← classifier accuracy
20: end while
21:
22: Candidate list← RFmodel(unseen data (NT))
23: return PPInetwork,NetStatistics, RandomForest, CandList
24: end procedure
Referring to algorithm 1, lines 2-9 perform the initial-
ization of key values. Based on the available information
on protein targets we label proteins as either a target or
nontarget. All proteins are then annotated with GO-slim,
any protein without an annotation of some form is removed
from the study. A binary matrix for training the random
forest is made which is then split 50/50 for train/test data,
the matrix consists of a series of 1’s’ for presence of a GO-
slim term and 0’s if it is not for each protein with the class
label for target/nontarget identify.
Lines 12 and 13 build the protein to protein interaction
network (PPI) and calculate a number of statistics, the
most important is the k-coreness for each protein. Lines
15-20 handle the training of the Random Forest classifier,
we modify the number of tree’s, the cutoff (the winning
class for an observation is the one with the maximum ratio
of proportion of votes to cutoff) to obtain the best model
based on confusion matrix and PR/ROC curves. When the
RF sampling has provided a useful classifier, line 22 passes
the unseen data (NT) through the trained RF classifier and
generates a list of candidate targets.
A graph is k-connected if every pair of vertices is con-
nected through at least k distinct paths, that do not share
edges. This property is related to the strength of a net-
work, a k-connected network remains connected whenever
fewer than k links are removed or broken. The k-core of
graph is a maximal subgraph in which each vertex has at
least degree k. The coreness of a vertex is k if it belongs to
the k-core but not to the (k+1) core. The cores represent
an important subgraph that contain functions of biologi-
cal significance. The formation of a hub node is the result
of the scale-free property of a network but the definition
of hubness is also a consequence of the size of the net-
work. Hubs are to found in most real-world networks and
have a significant impact on the topology, but they highly
unlikely to be formed in a random network.
3. Results
The first stage was to assess the impact of study bias of
the known protein connectivity patterns. The data are the
result of scientific experiments that may have concentrated
on the better known or more ’glamorous’ proteins. That
is to say proteins with few connections may be the result
of neglect on the part of the scientific community and not
because these proteins do not have an important role.
In figure 2 the frequency counts of the types of protein
targets is displayed, the most predominant type is GPCR.
We removed any protein type with fewer than 50 records as


















































































Figure 2: Breakdown of protein types (13,735 unique proteins) from
DrugCentral database.
We created the protein networks using the available pro-
teins. In figure 3 the degree of the network is plotted
against the cumulative distribution function and it is ev-
ident that a powerlaw exists in the network. That is we
have many proteins with few connections but there are
a small number of proteins with several hundred connec-
tions.
Complex networks were constructed using the protein
interaction data and annotated each node with informa-
tion regarding its status as a drug target, disease protein,





















Figure 3: Protein network degree with power law evident indicating
the non-random network structure. The dotted line represents the
90th percentile cut-off point for determining if a protein is a hub. In
this network, a degree of 17 is required giving 300 hubs.
The overall network statistics based on connectivity pat-
terns of 15726 nodes with 109,953 links gave: Modular-
ity of 0.37, Average path length of 3.81, Transitivity of
0.053, Diameter of 11 and is fully connected with no dis-
connected (isolates) proteins. Table 2 shows the top 20
proteins ordered according to the betweenness statistics,
this produces a very large value and is related to the de-
gree of each individual node, these nodes have the largest
number of connections to other proteins. The closeness
statistic is reasonably constant for these 20 proteins and
implies that they have similar characteristics. The hub-
ness value also varies little with these proteins and sug-
gests that connectivity patterns are similar. The centrality
measure is computed using the alpha centrality method,
which is less likely to encounter problems with asymmetric
matrices. The community measure indicates that these 20
proteins generally cooperate with few other communities
or modules. A community is usually interpreted as a bio-
logical function or process. However, we must be careful
not to infer too much from the network statistics alone the
next stage is to annotate the network proteins with gene
ontology (GO) terms. Determining biological plausibility
through GO provides a more valid interpretation.
Table 3 gives the protein statistics organized by hubness,
the top 20 proteins are dominated by ribosomal proteins,
these are the organelles that catalyze protein synthesis.
They form 45 tightly clustered communities.
Not all of the important proteins can be classed as
hub-like, a number of proteins with low degree but
high betweenness may account for 30% of the avail-
able proteins in a PPI network. These would not be
highly rated as potential drug targets under the usual
statistical criteria but some have the potential to be
considered as targets. We employed GO-slim anno-
Table 2: Highest scoring 20 proteins ordered according to between-
ness
close degree between hub central comm
HSP90AB1 5e-08 454 1353987 0.093 15 13.0
GRB2 6e-08 452 1228333 0.12 18 18.0
GOLGA2 5e-08 340 632816 0.13 36 8.0
ATXN1 4e-08 276 593291 0.051 29 11.0
ZDHHC17 3e-08 249 502844 0.053 33 11.0
KDM1A 3e-08 224 399557 0.069 32 11.0
TRIM27 4e-08 258 393388 0.12 65 8.0
KRT40 3e-08 333 379048 0.14 58 8.0
MAPK6 3e-08 201 363744 0.058 47 11.0
UBE2I 4e-08 202 351061 0.063 58 11.0
HSPA8 3e-08 199 347256 0.038 37 11.0
EGFR 4e-08 196 339368 0.05 24 11.0
LZTS2 4e-08 244 338341 0.094 12 8.0
TERF1 3e-08 218 332496 0.074 39 11.0
TRAF2 4e-08 214 332495 0.074 59 8.0
MEOX2 3e-08 210 313349 0.094 62 8.0
CRK 3e-08 216 307830 0.045 36 11.0
UBQLN4 3e-08 177 305193 0.042 26 11.0
REL 3e-08 197 295228 0.056 2 8.0
RBPMS 3e-08 220 287819 0.065 17 8.0
Table 3: Highest scoring 20 proteins ordered according to hubness
close degree between hub central comm
RPL37A 1e-08 138 30867 1.00 9.03 45.0
RPL18 1e-08 143 39136 0.98 9.81 45.0
RPS8 1e-08 132 34027 0.96 41.24 45.0
RPS3A 1e-08 106 38479 0.93 13.31 45.0
RPL18A 2e-08 138 47331 0.93 20.43 45.0
RPL14 1e-08 117 25628 0.90 61.55 45.0
RPL30 1e-08 129 32356 0.89 3.81 45.0
RPS2 2e-08 129 65550 0.88 0.44 45.0
RPL7A 1e-08 82 9141 0.85 17.27 45.0
RPL5 1e-08 87 13180 0.84 18.64 45.0
RPS13 1e-08 76 2923 0.83 11.48 45.0
RPL4 1e-08 79 13453 0.83 28.97 45.0
RPL10A 1e-08 83 12913 0.82 10.64 45.0
RPS3 1e-08 86 17144 0.81 13.83 45.0
RPL6 1e-08 99 21401 0.80 13.30 45.0
RPL7 1e-08 94 13661 0.80 13.28 45.0
RPS16 1e-08 73 3639 0.80 6.59 45.0
RPS6 1e-08 77 14896 0.78 36.98 45.0
RPS14 1e-08 115 35086 0.77 37.49 45.0
RPS4X 1e-08 77 13443 0.77 16.60 45.0
tations (http://www.geneontology.org/page/go-slim-and-
subset-guide) rather than apply all known GO annota-
tions to the proteins, we wished to apply a general level of
terms that provide a computationally tractable solution.
The generic GO-slim term set provides 149 terms across
the Cellular Component, Biological Process and Molecular
Function databases.
The data was highly imbalanced between the non-
targets (10,000 proteins) and the targets (1,449 proteins),
this adversely affected the initial classifiers with accura-
cies dropping to 45% since the more numerous non-target
class tended to predominate the classifiers. The nature of
the data implied we could not upsample using SMOTE or
similar techniques, therefore we down sampled the train-
ing protein data to give more balanced training set. This
allowed a Random Forest based classifier to be success-
fully constructed using the 149 ontology terms as variables.
This gave a matrix 149 x 6000: 149 terms (independent
variables) and 6,000 proteins unevenly divided into target
and non-target classes. The overall accuracy of the ontol-
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ogy based classifier is 74%, proving it has reasonable ac-
curacy at discriminating protein targets from non-targets
using ontological terms, 12 re-samples were used and the
forest was composed of 5000 trees. Recalling table 1, the
split in data was 50% assigned to the training set and 50%
of data in the test/validation set. The ROC curves for test
data are shown in figure 4a.
The receiver operating characteristic curve (ROC) is
based on evaluating the tradeoffs between specificity and
sensitivity. Specificity is the probability of predicting a
target given the true state is in fact a target, whereas sen-
sitivity is the probability of predicting a non-target given




Negative Predictive Value = 0.97%
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The random forest has misclassified 1,434 nontargets as
targets and 99 targets as nontargets. It has correctly iden-
tified 626 targets and 3,849 nontargets. The accuracy for
the targets is much higher than for nontargets because
the sampling procedure we used placed a higher value on
correctly identifying targets. Since the the data is highly
imbalanced with some overlap this was a necessary trade-
off.
The RandomForest classifier uses Gini index to rank
each GO predictor term for it’s contribution to discrim-
inating between protein targets and non-targets. This in-
formation is displayed in table 4 with the highest scoring
15 predictors out of 149.
In figure 4 the precision-recall curves are presented, this
shows the precision values for corresponding sensitivity
(recall) values. Similar to the ROC plot, the PR plot pro-
vides a model-wide evaluation. However, precision is di-
rectly influenced by class imbalance and does take the TN
(true negatives) into consideration. The precision-recall
curve highlights the tradeoff between precision and recall,
where a high area under the curve represents both high
recall and high precision. High precision relates to a low
false positive rate, and high recall relates to a low false
negative rate. High scores for both criteria, indicate that
the classifier is returning accurate results (high precision),
as well as returning a majority of all positive results (high
recall). Any classifier with high recall but low precision
returns many results, but the majority of its predicted la-
bels are incorrect when compared to the training labels.
A classifier with high precision but with low recall will re-
turn very few results, but most of its predicted labels are
correct when compared to the training labels.
Examining figure 4, there appears little difference be-
tween the classifiers with perhaps the purple line (no sam-
pling) having the best performance. This is because not
using sampling will produce a classifier that will allow the
majority class to dominate, hence a greater accuracy is
produced by always predicting it. Together with the ROC
curve the precision-recall curve indicate the performance
level for the random forest.
Table 4: Top 15 GO Term predictor importance ranked on Gini score
generated from the RandomForest classifier
GOterm Type Description Value
GO:0016301 MF kinase activity 86.37
GO:0044281 BP small molecule metabolic.process 59.43
GO:0043167 MF ion binding 30.58
GO:0004871 MF signal transducer activity 29.86
GO:0005886 CC plasma membrane 27.04
GO:0055085 BP transmembrane transport 20.54
GO:0022857 MF transmembrane transporter activity 20.17
GO:0016491 MF oxidoreductase activity 18.89
GO:0007165 BP signal transduction 14.61
GO:0008233 MF peptidase activity 13.84
GO:0006464 BP cellular protein modification process 12.03
GO:0005615 CC extracellular space 11.58
GO:0006950 BP response to stress 10.87
GO:0042592 BP homeostatic process 9.04
GO:0006810 BP transport 8.20
The variable importance is calculated by the ’impurity’
from the Gini index for splitting (deciding when to make
splits on the input variables and when to stop growing the
trees). At each split the importance of the variable is accu-
mulated for every tree for that variable. For classification
tasks such as this one, the Random Forest keeps a tally of
each tree’s output and then takes a majority vote to de-
cide the overall class output. Further understanding of the
classifier was gained when a breakdown of the GO terms
giving frequency counts between targets and non-targets
was made.
The term GO:0016301 for kinase activity was the
strongest variable with a score of 86.37, the second
key variable was term GO:0044281 for small molecule
metabolic processes at 59.43. The third highest scoring
variable was GO:0043167 which codes for ion binding with
a value of 30.58. Examining the frequency counts of the
differences between the presence or absence of an ontologi-
cal term is presented in figure 5. The frequency counts for
the presence (red bars) or absence (cyan) of a GO term
for targets and non-targets. The present’ category is gen-
erally the most predominant, the absent category is more
frequent for the target proteins and thus discriminates be-
tween the non-targets.
The k-core of a graph relates to the maximal connected
subgraph, the vertices of which must have at least of de-
gree k within the subgraph. It is a useful technique for
examining network connectivity where it is important to
detect community and clusters. However, it can be quite
interesting to visualize the coreness structure of small or
medium networks. In figure 6 we show an example can-
didate protein and its neighbors. As a statistic, the nu-
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(b) The Precision and Recall curves for test data
accuracy
Figure 4: ROC and PR for several sampling strategies. The overall accuracy on test data is 74%
targets. We examined the medians and IQR for the two
groups and for targets the median=2, IQR=6, for nontar-
gets median=5 and IQR=8. The k-coreness is too over
dispersed to discriminate between targets and nontargets
but is useful for further analysis when targets are identified
by the classifier.
Examining the MIPS protein complex database it would
appear that most of the k-plex cores are part of protein
complexes. We examined the most significant GO terms
among k-plex core members are ranked and again we ex-
amined the protein types associated with these k-cores (be-
tween targets and non-targets). The conclusion is that the
location of a node is more important than the number of its
connections or the number of connections of near neigh-
bors. The k-coreness criteria is a better indicator of a
nodes influence on biological function (target value) than
degree.
The next stage of the analysis required generating a
third list of proteins that were not drug targets but had
GoSlim ontology annotations. The first and second lists
of proteins refer to the targets and non-targets used to
build and test the RandomForest classifier. Third list pro-
teins that were identified as target-like by the classifier
were examined at the k-coreness level to determine net-
work neighborhood and likely importance.
In table 5 the list of potential protein targets identified
by our system are displayed. They are ordered according
to their probability score, the likelihood they are target
proteins. The first column gives the protein type and the
second column identifies the protein name. The third col-
umn identifies the protein as a hub or non hub (based on
our criteria) and the fourth column gives the probability
score of the protein as a likely target (derived from the
Random Forest outputs). The fifth column provides the
k-coreness score, the sixth column provides evidence found
from literature or other sources that the protein has been
proposed as a drug target.
The final stage of the analysis takes the generated a list
of candidate target proteins along with their characteris-
tics as identified in table 5 and to place them them in
the context of available drugs. Previous work by Yaman-
ishi considered four possible approaches to this problem
[30, 29]: (i) new drug candidate compounds versus known
target proteins, (ii) known drugs versus new target candi-
date proteins, (iii) new drug candidate compounds versus
known target candidate proteins, (iv) known drugs versus
known target candidate proteins. We tackle class (ii), be-
cause we are introducing previously unknown/untargeted
proteins.
Based on the protein class (e.g. enzyme, GPCR, Trans-
porter etc) of our candidates we assessed the chemical
structure and pharmacological properties of drugs target-
ing proteins of these types. We filled in missing pro-
tein class data from other sources. The characteristics of
GPCR, Ion Channel, Transporter and enzyme class pro-
teins were profiled based on the chemical structure and
pharmacological similarity scores of the drugs targeting
them.
Examining table 5 reveals that the highest scoring k-
coreness proteins are generally hubs. That is to say they
have over 17 connections to other proteins. However, their
k-coreness score indicates they are centrally placed in the
network and is not an indicator for “targetness”. The ma-
jority of candidates are non-hubs with fewer connections
although their k-coreness score is between 12 and 2. We


































































































































































































































































































































































































































































(b) GO term frequencies for targets
Figure 5: The frequency counts for the presence (red bars) or absence (cyan) of a GO term for targets and non-targets. The y-axis is broken
to highlight the differences between them. The present’ category is generally the most predominant. The absent category is more frequent
for the target proteins and thus discriminates between the non-targets
is an amyloid beta precursor like protein 1, it is involved in
synaptic maturation during cortical development and has
been associated with late-onset of Alzheimer’s disease. It
has a k-coreness rank of 16 and a neighborhood of 45 inter-
connected proteins, four of which have 13 drugs targeted
at them. The APLP1 protein is located in a reasonably ac-
tive part of the drugome. Experimental evidence indicates
that Copper and also Herapin (Heparin has anti-clotting
properties) binds to this protein. A similarity search based
on amino acid sequence reveals it is similar to APLP2 and
APP, both are linked to Alzheimer’s. Referring to table
6 the drugs targeted at the four APLP1 partners are dis-
played.
The protein PNP (Purine Nucleoside Phosphorylase)
has been implicated in adenosine deaminase deficiency and
lesch-nyhan syndrome. The main clinical indication is re-
current infections due to severe T-cell immunodeficiency.
Other patients may also suffer from neurologic impair-
ment. The TK1 (Thymidine Kinase 1) is a cytosolic en-
zyme that catalyzes several components and is used as
a biomarker in a number cancers (colorectal cancer, lung
and leukemia). CDK4 (Cyclin Dependent Kinase 4) is a
catalytic component of the protein kinase complex that
is important for cell cycle G1. Mutations in this pro-
tein are also associated with a variety of cancers. The
SAT1 (Spermidine/Spermine N1-Acetyltransferase 1) pro-
tein is a rate-limiting enzyme in the catabolic pathway of
polyamine metabolism. It is implicated in Keratosis Fol-
licularis which is a rare, inherited skin condition disease.
We accessed the STITCH database which contains ex-
perimental evidence and also predicted information for the
ALPL1 protein. It is centrally placed at the locus of sev-
eral diseases, drugs and other proteins thus may be playing
an as yet unknown role. We examined the role of the top
10 proteins for evidence of potential use as drug targets,
these are displayed in table 7.
The NUDT18 (Nudix Hydrolase 18) protein functions
to eliminate potentially toxic nucleotide metabolites from
the cell and regulate concentration levels of cofactors and
signaling molecules. CCNB1 (Cyclin B1) is a regulatory
protein involved in mitosis and is involved in several can-
cers such as nasopharyngeal carcinoma and adrenal car-
cinoma. It has several drugs targeted such as Temo-
zolomide, Nocodazole and Purvalanol. The PIP4K2A
(Phosphatidylinositol-5-Phosphate 4-Kinase Type 2 Al-
pha) protein and is involved in the regulation of secre-
tion, cell proliferation, differentiation and motility. It is
implicated in leukemia and acute lymphoblastic tumors.
It is currently undergoing investigation with Adenosine
triphosphate (ATP) as a potential intervention.
The GALNS (Galactosamine (N-Acetyl)-6-Sulfatase)
protein is involved in mucopolysaccharidosis which an au-
9
Table 5: Potential target proteins identified by RandomForest classifier and measures calculated for k-coreness criteria. Keeping proteins
with probability (>0.8) and sorted by k-coreness (> 1), we have approximately 50 target protein candidates.
TargetClass Gene myhubs prob core
1 Unknown APLP1 hub 0.85 16
2 Enzyme NUDT18 hub 0.95 15
3 Unknown CCNB1 hub 0.81 14
4 Kinase PIP4K2A hub 0.94 14
5 Enzyme GALNS hub 0.88 13
6 Kinase PBK hub 0.97 13
7 Unknown NPPA hub 0.88 13
8 Unknown LRRC8A hub 0.84 13
9 Unknown KIR3DS1 hub 0.85 13
10 Unknown PSME2 hub 0.82 13
11 Kinase STK40 hub 0.94 12
12 Kinase PRKAG1 hub 0.86 12
13 Unknown LRRC8E hub 0.81 12
14 Kinase PRKACG hub 0.95 12
15 Unknown NME2 hub 0.95 11
16 Kinase KSR1 hub 0.89 10
17 Kinase MAP3K14 non-hub 0.95 10
18 Enzyme ADSL hub 0.82 10
19 Kinase PSKH2 hub 0.85 10
20 Enzyme BLVRA hub 0.81 9
21 Unknown RASSF2 non-hub 0.85 9
22 Enzyme GAD1 non-hub 0.83 8
23 Kinase CKM hub 0.88 8
24 Unknown ERLIN2 non-hub 0.83 8
25 Enzyme FAM20C non-hub 0.89 7
26 Kinase CDK20 non-hub 0.92 6
27 Enzyme DHTKD1 non-hub 0.82 6
28 Unknown C8G non-hub 0.87 6
29 Kinase TSSK6 non-hub 0.91 6
30 Enzyme NLN non-hub 0.88 5
31 Enzyme NUDT9 non-hub 0.84 5
32 Unknown FGF10 non-hub 0.90 5
33 Enzyme SDHAF2 non-hub 0.86 5
34 Transporter SLC6A6 non-hub 0.94 5
35 Kinase PIKFYVE non-hub 0.87 5
36 Unknown CNNM4 non-hub 0.87 4
37 Enzyme SULT1B1 non-hub 0.82 4
38 Unknown PEX2 hub 0.82 3
39 Enzyme GOT1L1 non-hub 0.82 3
40 Enzyme AMDHD2 non-hub 0.85 3
41 Unknown GART non-hub 0.81 3
42 Enzyme UQCC2 non-hub 0.86 3
43 Transporter SLC2A3 non-hub 0.93 3
44 IC FXYD7 non-hub 0.86 3
45 Kinase PRPS1L1 non-hub 0.89 2
46 Transporter SLC16A2 non-hub 0.96 2
47 Unknown FDX1L non-hub 0.95 2
48 Enzyme HAO1 non-hub 0.82 2
49 Enzyme CBR4 non-hub 0.85 2
50 Enzyme HAGH non-hub 0.81 2
Table 6: The drug targeted proteins in the APLP1 module (k-
coreness) network.
DrugName TargetClass Gene
2 Mercaptopurine Enzyme PNP
3 Sorafenib Unclassified PNP
4 Brivudine Kinase TK1
5 Idoxuridine Kinase TK1
6 Zidovudine Kinase TK1
7 Broxuridine Kinase TK1
8 Sunitinib Kinase CDK4
9 Quercetin Kinase CDK4
10 Ruboxistaurin Kinase CDK4
11 Ceritinib Kinase CDK4
12 Nintedanib Kinase CDK4
13 Ribociclib Kinase CDK4
14 Pentamidine Enzyme SAT1
tosomal recessive lysosomal storage disease caused by build
up of keratan sulfate. The main features include short
stature and skeletal dysplasia. Several drugs such as elo-
sulfase are undergoing trials. The PBK (PDZ Binding Ki-
Table 7: Evaluation of the first 10 candidate target proteins. The
larger the k-core, then usually more drugs will be involved in the
network
Gene k-core size Drugs Target Evidence
APLP1 16 22 Yes (Simons, 2002)
NUDT18 15 2 Tentative (Takagi, 2012)
CCNB1 14 17 Yes (Momeny, 2017)
PIP4K2A 14 12 Tentative (Bekker-Mndez, 2017)
GALNS 13 2 Yes (Hiramatsu, 2017)
PBK 13 1 Yes (Yang, 2017)
NPPA 13 55 Yes (Lynch, 2012)
LRRC8A 13 162 Tentative (Platt, 2017)
KIR3DS1 13 1 Yes (Pyo, 2013)
PSME2 13 10 Yes (Gomes-Alves ,2010)
nase) protein has recently been associated with malignant
process of cancers and may be involved in the activation of
lymphoid cells and various testicular functions. The NPPA
(Natriuretic Peptide A) protein is involved in the control
of extracellular fluid volume and electrolyte homeostasis.












































Figure 6: The protein APLP1 and its subnetwork indicating k-
Coreness. The colors indicate the centrality of the subnetworks: red
or yellow nodes are on the periphery, green and cyan represent the
nearest neighbors while the central nodes are blue or purple. The
plotting algorithm attempts to obtain a circular pattern where pos-
sible to highlight the k-cores
problems, a number of drugs such as Chlorthalidone are
targeted at NPPA.
The LRRC8A (Leucine Rich Repeat Containing 8
VRAC Subunit A) is part of a family of proteins that
are involved in many biological processes, such as cellu-
lar trafficking and cell adhesion. It is implicated in several
immunodeficiency problems highlighted by low or absent
serum antibodies and low or absent circulating B-cells.
The KIR3DS1 (Killer Cell Immunoglobulin Like Recep-
tor, three Domains and Short Cytoplasmic Tail) protein
are transmembrane glycoproteins formed by killer cells
and T cells. Killer-cells are highly polymorphic and this
causes problems developing treatments and are thus an
research active area. The PSME2 (Proteasome Activa-
tor Subunit 2) protein is distributed throughout eukary-
otic cells at a high concentration and cleave peptides in
an ATP/ubiquitin-dependent process in a non-lysosomal
pathway. It is implicated in problems such as ulceroglan-
dular tularemia and cystic fibrosis, which are targeted by
Bortezomib, Carfilzomib and other drugs.
Examining the k-core statistic, we find that the larger
the k-core module the more likely there will be drugs al-
ready targeting the disease implicated proteins in the net-
work neighborhood. This is confirmed by the information
in table 7 and also table 5. It must be recalled that in
the databases used in our study there is no mention of
these proteins as targets. The Random Forest classifier
has identified these proteins based on their gene ontology
annotations. Some of the classifier discovered targets are
in fact already targets, unfortunately this information was
not available in our database. However, it has demon-
strated the reliability and validity of our technique.
4. Conclusions
The method described in this paper presents a novel ap-
proach for considering the viability of previously unrecog-
nized/untargeted proteins as potential drug targets. We
stress that full validation can only be achieved through
using in-vitro, animal tissue and ultimately human tissue
experiments. Our method provides an in-silico approach
for generating lists of candidate targets that have rank-
ings on several criteria such as biological similarities with
known targets, protein type and complex network statis-
tics describing the protein network neighborhood. The
latter may play a role in the patient developing unwanted
side-effects. We determined that both structure and con-
nectivity patterns are necessary for identification of target
proteins but this information needs to be coupled with bi-
ological knowledge. The use of Gene Ontology provides
a biologically plausible method of protein annotation and
assessment for further consideration as a target. In terms
of limitations, we can say nothing about drug overall effi-
cacy or long term effects on the predicted targets. Nor do
we consider the mode of drug action or pharmacological
action. Future work will address the issues of drug repo-
sitioning in a principled way using some of the methods
described here.
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